CN102961508A - Traditional Chinese medicine composition used for treating prostatitis and benign prostatic hyperplasia - Google Patents
Traditional Chinese medicine composition used for treating prostatitis and benign prostatic hyperplasia Download PDFInfo
- Publication number
- CN102961508A CN102961508A CN2012105414606A CN201210541460A CN102961508A CN 102961508 A CN102961508 A CN 102961508A CN 2012105414606 A CN2012105414606 A CN 2012105414606A CN 201210541460 A CN201210541460 A CN 201210541460A CN 102961508 A CN102961508 A CN 102961508A
- Authority
- CN
- China
- Prior art keywords
- parts
- chinese medicine
- medicine composition
- parched
- prostatic hyperplasia
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Abstract
The invention belongs to the technical field of medicines and relates to a traditional Chinese medicine composition used for treating prostatitis and benign prostatic hyperplasia and a preparation method thereof. The traditional Chinese medicine composition used for treating prostatitis and benign prostatic hyperplasia provided by the invention is prepared from the following traditional Chinese medicine composition raw drugs in parts by weight: 70-100 parts of fried peach kernel, 70-100 parts of fried myrrh, 70-100 parts of salvia miltiorrhiza, 70-100 parts of red peony root, 70-100 parts of safflower, 70-100 parts of herba lycopi, 70-100 parts of fried cowherb seed, 70-100 parts of spina gleditsiae, 265-295 parts of herba patriniae, 265-295 parts of dandelion, 70-100 parts of szechwan Chinaberry fruit, 70-100 parts of angelica root, 125-155 parts of herba pyrrosiae and 70-100 parts of medlar. The traditional Chinese medicine composition provided by the invention has the efficacies of activating blood and dissolving stasis as well as clearing heat and promoting diuresis; and the traditional Chinese medicine composition provided by the invention is used for treating stranguria caused by blood stasis condensation, symptoms such as downward flow of dampness heat, urinary urgency, painful urination, unsmooth urination and drop leak and prostatitis and benign prostatic hyperplasia patients with the symptoms.
Description
Technical field
The invention belongs to medical technical field, be specifically related to a kind of Chinese medicine composition that is used for the treatment of prostatitis, prostatic hyperplasia and preparation method thereof.
Background technology
Prostatitis and prostatic hyperplasia are the common diseases of male prostate.
The sickness rate of chronic prostatitis (ChronicProstatitis, CP) is high, and therapeutic effect is poor, is one of important illness of puzzlement adult male always, has a strong impact on routine work and life.According to statistics, the male of China more than 35 years old has and suffers from primary disease more than 45%, accounts for more than 40% of urology department outpatient clinic patient; Have every year 2000000 patients medical in the U.S., Epidemiological study is 5%-8.8%.According to estimates, the male within a certain period, has 50% to be subject to the puzzlement of prostatitis symptom in life.Since cause cause of disease complexity, the prostate dissection of CP special, clinically with complicated symptoms, course of disease delay, recurrence etc. is feature easily, modern medicine and pharmacology treatment curative effect is unsatisfactory.
Prostatic hyperplasia is commonly called as prostate hyperplasia, refers to owing to prostate parenchyma quantity increases the increase that causes prostate volume, is the movable result who strengthens of cell mitogen that a variety of causes causes, its feature shows as substrate and epithelial hypertrophy.Prostatic hyperplasia is one of elderly men commonly encountered diseases, generally begins to occur the pathological change of hypertrophy after 40 years old, occurs related symptoms after 50 years old.The sickness rate of hyperplasia of prostate increases progressively with age growth, but clinical symptoms is the most obvious with 61～70 years old.The prostatic hyperplasia cardinal symptom has dysuria, frequent micturition, urinate initial slow, the urine line is unable, urine is interrupted or the sound of rain pattering etc., also acute urinary retention, urinary retention with overflow incontinence can occur what is more.At present, it is not fully aware of that hyperplasia of prostate former carried on as before, and it is generally acknowledged relevant with elderly men dihydrotestosterone gathering in body of gland.Patients with Prostatic Hyperplasia such as early diagnosis are also thoroughly treated, and can recover the function of normal voiding.At present the Treatment of Benign Prostatic Hyperplasia mode mainly is divided into operative treatment and Drug therapy, because operative treatment is a kind of traumatic and destructive procedure, patient is had certain potential risk, thus the patient more be ready to make to heal with medicine, with the risk of avoiding performing the operation.
Therefore, good in the urgent need to a kind of clinical efficacy, safety, toxic and side effects is little, the medicine that patient is easy to accept.
Patent 200510044832 discloses a kind of medicine for the treatment of prostatitis, prostatic hyperplasia, and this medicine is the medicament made from the herbal raw material of Semen Persicae (parched) 6-20, Myrrha (parched) 3-15, Radix Salviae Miltiorrhizae 6-20, Radix Paeoniae Rubra 6-20, Flos Carthami 6-15, Herba Lycopi 6-20, Herba Patriniae 10-60, Herba Taraxaci 10-60, Fructus Toosendan 3-20, Radix Angelicae Dahuricae 3-20 weight portion proportioning.This medicine plays better therapeutic effect to prostatitis, prostatic hyperplasia, but this medication journey is longer, show to serve on three courses for the treatment of from clinical test results after its curative effect just comparatively satisfied.
Summary of the invention
The purpose of this invention is to provide a kind of to prostatitis, prostatic hyperplasia determined curative effect and the pure Chinese medicine that has no side effect, to satisfy the demand of extensive patients.
Another object of the present invention provides the preparation method of the oral formulations of this medicine.
The present invention is achieved by the following technical solutions:
A kind of Chinese medicine composition that is used for the treatment of prostatitis, prostatic hyperplasia is prepared from by the traditional Chinese medicinal composition raw materials of following weight proportion: Semen Persicae (parched) 70-100 part, Myrrha (parched) 70-100 part, Radix Salviae Miltiorrhizae 70-100 part, Radix Paeoniae Rubra 70-100 part, Flos Carthami 70-100 part, Herba Lycopi 70-100 part, Semen Vaccariae (parched) 70-100 part, Spina Gleditsiae 70-100 part, Herba Patriniae 265-295 part, Herba Taraxaci 265-295 part, Fructus Toosendan 70-100 part, Radix Angelicae Dahuricae 70-100 part, Folium Pyrrosiae 125-155 part, Fructus Lycii 70-100 part.
Above-mentioned weight proportion is preferably: Semen Persicae (parched) 80-90 part, Myrrha (parched) 80-90 part, Radix Salviae Miltiorrhizae 80-90 part, Radix Paeoniae Rubra 80-90 part, Flos Carthami 80-90 part, Herba Lycopi 80-90 part, Semen Vaccariae (parched) 80-90 part, Spina Gleditsiae 80-90 part, Herba Patriniae 275-285 part, Herba Taraxaci 275-285 part, Fructus Toosendan 80-90 part, Radix Angelicae Dahuricae 80-90 part, Folium Pyrrosiae 135-145 part, Fructus Lycii 80-90 part.
Above-mentioned weight proportion optimum is: 85 parts of Semen Persicae (parched)s, 85 parts of Myrrha (parched), 85 parts of Radix Salviae Miltiorrhizaes, 85 parts of Radix Paeoniae Rubra, 85 parts on Flos Carthami, 85 parts of Herba Lycopi, 85 parts of Semen Vaccariae (parched)s, 85 parts of Spina Gleditsiaes, 280 parts of Herba Patriniae, 280 parts of Herba Taraxacis, 85 parts of Fructus Toosendans, 85 parts of the Radixs Angelicae Dahuricae, 140 parts of Folium Pyrrosiae, 85 parts of Fructus Lycii.
In above composition the of the present invention, the weight of each medicine of distinguishing the flavor of is calculated with crude drug, if in grams, above-mentioned prescription forms the pharmaceutical preparation that can be made into a dosage schedule, if day takes 2-4 time, is 20-40 days dose, as make preparation, then can be made into the 100-1000 agent because of varying in size of preparation.Described 100-1000 agent refers to the dosage form of unit dose, such as tablet 100-1000 sheet, and capsule 100-1000 grain, granule l00-1000g, oral liquid l00-l000ml, unguentum l00-l000g, pill 10-1000 ball etc.
More than form to be by weight as proportioning, when producing, can to increase or reduce according to corresponding proportion, can be take kg as unit such as large-scale production, or take the t(ton) be unit; Preparation also can be take g as unit on a small scale.Weight can increase or reduce, but the constant rate of the raw medicinal herbs weight proportion between each composition.
The ratio of above weight proportion obtains through science screening, for especial patient, and such as serious symptom or light disease, fat or modest patient, the proportioning of the amount that can corresponding adjustment forms increases or reduces being no more than 100%, and drug effect is substantially constant.
Chinese medicine composition of the present invention can be made any pharmaceutically useful peroral dosage form when making pharmaceutical preparation, these dosage forms are selected from: tablet, capsule, oral liquid, suck agent, granule, pill, powder, pill preferably, tablet, capsule, granule, most preferably capsule.
The present invention is used for the treatment of the preparation method of the Chinese medicine composition of prostatitis, prostatic hyperplasia, the process following steps:
(a) Myrrha, Spina Gleditsiae, the Radix Angelicae Dahuricae are ground into fine powder, and be for subsequent use;
(b) all the other Semen Persicaes, Radix Salviae Miltiorrhizae, Radix Paeoniae Rubra, Flos Carthami, Herba Lycopi, Semen Vaccariae (parched), Herba Patriniae, Herba Taraxaci, Fructus Toosendan, Folium Pyrrosiae, Fructus Lycii, extracting in water filters, merging filtrate, filtrate is condensed into thick paste;
(c) add the fine drug powder that makes in the step (a), dry below 80 ℃, be ground into fine powder, mixing is made pharmaceutically active substance.
(d) this active substance mixes separately or with the medicine acceptable carrier, namely can be made into according to the galenic pharmacy conventional method.
Chinese medicine composition of the present invention can add some medicine acceptable carriers as required, can adopt the galenic pharmacy routine techniques to prepare this pharmaceutical preparation, as pharmaceutically active substance is mixed with the medicine acceptable carrier.The acceptable carrier of described medicine is selected from: Mel, refined honey, mannitol, sorbitol, sorbic acid or potassium salt, sodium pyrosulfite, sodium sulfite, sodium thiosulfate, cysteine hydrochloride, TGA, methionine, vitamin A, vitamin C, the main plain E of dimension, vitamin D, azone, EDETATE SODIUM, Ethylenediaminetetraacetic Acid Calcium Salt, the alkali-metal carbonate of monovalence, acetate, phosphate or its aqueous solution, hydrochloric acid, acetic acid, sulphuric acid, phosphoric acid, aminoacid, sodium chloride, potassium chloride, sodium lactate, xylitol, maltose, glucose, fructose, dextran, glycine, starch, sucrose, lactose, mannitol, silicon derivative, cellulose and derivant thereof, alginate, gelatin, polyvinylpyrrolidone, glycerol, propylene glycol, ethanol, soil temperature 60-80, span-80, Cera Flava, lanoline, liquid paraffin, hexadecanol, gallate ester, fine jade, triethanolamine, basic amino acid, carbamide, allantoin, calcium carbonate, calcium bicarbonate, surfactant, Polyethylene Glycol, cyclodextrin, beta-schardinger dextrin-, the phospholipid material, Kaolin, Pulvis Talci, calcium stearate, magnesium stearate etc.
Chinese medicine preparation of the present invention, when making medicament, the medicament of unit dose can contain pharmaceutically active substance 0.1 ~ l000mg of the present invention, and all the other are pharmaceutically acceptable carrier.Pharmaceutically acceptable carrier can be 0. 01-99. 9% of total formulation weight amount by weight.
Chinese medicine composition of the present invention has blood circulation promoting and blood stasis dispelling, the effect of clearing away heat-damp and promoting diuresis.Be used for the stranguria due to blood stasis cohesion, the damp invasion of lower energizer, disease sees urgent micturition, dysurea, it is smooth to urinate, the sound of rain pattering is unclean; Chronic prostatitis, prostatic hyperplasia are seen above-mentioned patient.
With the passing of time Chinese medicine composition of the present invention is particularly useful for the course of disease, the patient who repeatedly shows effect, and curative effect is more outstanding.
Pharmaceutical preparation of the present invention is determined usage and dosage according to patient's situation in use.Instructions of taking due to illness people's body constitution situation is taken to the ill, as taking 1-4 time each 4-6 grain day.
Chinese medicine composition pharmaceutical research of the present invention:
One, anti-inflammatory effect
1, the mice foot swelling that causes of Chinese medicine composition on Carrageenan of the present invention has obvious inhibitory action.Chinese medicine composition high dose group of the present invention (9g/kg/ day) causes scorching rear two hours foot swelling rates with matched group and is respectively 10.8 ± 4.2%, 22.3 ± 8.8% both than significant difference (P＜0.001) is arranged, it is 15. 04 ± 9.6% that Chinese medicine composition low dose group of the present invention (4.5g/kg/ day) causes scorching 2 hours foot swelling rates, and causing scorching 4,6,8,24 hours foot swelling rates under the high and low dose has significant differences with normal saline group ratio.Antiinflammatory action was better than QIANLIEKANG (P〉0.05) when Chinese medicine composition low dose group of the present invention caused scorching 6 hours.
2, Chinese medicine composition of the present invention obviously suppresses the mice ear effect that Oleum Tiglii causes: the ear swelling rate is respectively 11.6 ± 6.0% under the high and low dose, 13.2 ± 5.4% with matched group 16.9 ± 2.8% P＜0.05 relatively.
3, Chinese medicine composition of the present invention obviously reduces capillary permeability, and Chinese medicine composition high dose group of the present invention infects area (cm
2) and optical density be respectively 1.99 ± 0.6,0.105 ± 0.03 with matched group 3.84 ± 0.85,0.183 ± 0.067 significant differences (P＜0.001) is arranged relatively.It is 2.31+ 0.82 and matched group ratio, P＜0.001 that low dose group infects area.
4, Chinese medicine composition of the present invention causes granuloma to cotton balls obvious inhibitory action: Chinese medicine composition high dose group granuloma dry weight of the present invention (mg) is 6.38 ± 2.56, Chinese medicine composition low dose group granuloma dry weight of the present invention is 5.68 ± 2.99, with the l3 .08 of normal saline group ± 9.69 than significant difference (P＜0.05) is all arranged.
Two, the immune Accommodation of Chinese medicine composition of the present invention
1, Chinese medicine composition of the present invention can significantly improve the carbon clearance index of immunologic hypofunction mice; It is 0.0391 ± 0.0156 that Chinese medicine composition of the present invention (9 g/kg/ day) is cleaned up index with the vinegar group, with vinegar add the normal saline group 0 0213 ± 0.0072 than significant difference (P＜0.001) is arranged.Show that Chinese medicine composition of the present invention can improve the macrophage phagocytic function of immunologic hypofunction, part improves the non-specific immunity of body.
2, Chinese medicine composition of the present invention can obviously suppress the delayed hypersensitivity of mice, the foot pad of Chinese medicine composition high and low dose group of the present invention increases thickness and is respectively 1.10 ± 0.45,1.34 ± 0.44 with the normal saline group 1.89+0.39 significant differences is arranged relatively, be respectively P＜0.001 and P＜0.01, show that Chinese medicine composition of the present invention obviously suppresses the cellular immune function of body.
3, Chinese medicine composition of the present invention can obviously improve the antibody generation of the mice of immunologic hypofunction, Chinese medicine composition of the present invention (9 g/kg/ day) is l8.39 ± 7.14 with the HC50 of vinegar group, vinegar can add normal saline HC50 be 4.48 ± 2.27 both significant differences (P＜0.001) is relatively arranged.This result shows that Chinese medicine composition of the present invention can improve the humoral immune function of the mice of immunologic hypofunction.
Three, Chinese medicine composition of the present invention mice prostatic hyperplasia inhibitory action that the third testis is caused
1, Chinese medicine composition of the present invention has obvious preventive effect to the mice prostatic hyperplasia that the third testis causes; Chinese medicine composition high and low dose group prostate index of the present invention be respectively the 1.51 ± 0.56,1.70 ± 0.43 and third testis add the normal saline group 2.67 ± 0.55 than significant difference (P＜.0.001 and P＜0.01) is arranged.Microscopy shows, Chinese medicine composition of the present invention can suppress secretion acinus, the acinus epithelium of body of gland, the hypertrophy of connective tissue.
2, Chinese medicine composition of the present invention has obvious therapeutical effect to the mice prostatic hyperplasia that the third testis causes.
Chinese medicine composition high dose group prostate index of the present invention is 1.11 ± 0.32, and low dose group is 1.31 ± 0.34, and adding 1.65 ± 0.65 of normal saline group with the third testis more all has significant difference to be respectively P＜0.01 and P＜0.05.Microscopy shows, Chinese medicine composition of the present invention can alleviate the hypertrophy of prostate secretion acinus, glandular epithelium and connective tissue that the third testis causes.
In sum, Chinese medicine composition of the present invention can obviously suppress four kinds of different inflammatory reactions under 4.5 ~ 9g/kg/ daily dose.Can significantly suppress the mice foot swelling that carrageenin causes and alleviate mice dimethylbenzene ear swelling, reduce the mice capillary permeability, suppress the granulomatous generation of cotton balls, demonstrate the effects such as obvious anti-inflammation detumescence and anti-proliferation of fibrous tissue.But the macrophage phagocytic function of the mice of Chinese medicine composition Promote immunity hypofunction of the present invention and the generation of hemolysin and improve non-specific immunity and the humoral immune function of immunologic hypofunction, the DTH that Chinese medicine composition of the present invention can suppress mice reacts and the cellular immune function of inhibition body, show that Chinese medicine composition of the present invention has the immunologic function Accommodation, this Accommodation helps the improvement of inflammation.Chinese medicine composition of the present invention can obviously alleviate the mice prostatic hyperplasia that the third testis causes, the prostatic hyperplasia that the third testis is caused has preferably preventive and therapeutic effect.
Acute toxicity test
Get 32 of mices, body weight 23-26g is divided into the first and second two groups, every group of male and female half and half at random.The first group gives medicinal composition solution of the present invention, and the second group gives normal saline in contrast.Gastric infusion is 3 times in equal 24 hours of each treated animal, then observes a week.Respectively weigh 1 time the 3rd, the 7th of administration, each group sampling half sacrifice of animal is dissected perusal after weighing.The result: all no abnormal after two groups of mice administrations, two groups of the activities of animal, chaeta, stool, feed have no significant difference.
Long term toxicity test:
The clinical adult's consumption of pharmaceutical composition of the present invention is 6-9g/ day (part is taken for 3 times).Long term toxicity test rat dosage is with reference to people (70kg) consumption (9g/ day), directly convert according to body weight, three groups of high, medium and low dosage groups respectively are 0.65g/100g, 0.39g/100g, 0.13g/100g, are equivalent to respectively 50 times, 30 times and 10 times of people's consumption.
In 180 days of successive administration, the animal appearance activity is no abnormal, dissects perusal during off-test, without unusually finding, gets important organ (heart, liver, lung, kidney, testis, ovary etc.) pathology microscopy and does not also find the pathological change relevant with medicine.
Clinical test results
Through seven hospital's experimental observations of phase iii clinical trial cooperative groups, the adult takes oral agents of the present invention, each 2-3 gram, and every day 3 times, taking continuously 28 days is a course for the treatment of, takes the accidental stomach discomfort person of medicine of the present invention, does not generally affect continual cure.The total effective rate of Drug therapy chronic prostatitis 279 examples of the present invention is 97.5%, and the total effective rate for the treatment of prostatic hyperplasia 200 examples is 90.0%.
Clinical trial proves: Drug therapy chronic prostatitis of the present invention is take the turbid stasis of blood coagulation type of Chinese medical discrimination, damp heat downward flowing type as best.Clinical observation is evident in efficacy to the improvement of its main syndromes, all reach more than 90% such as the effective percentage of pudendum distending pain, lower abdomen contracture, waist dull pain and dribbling urination, puckery pain, with matched group relatively, significant difference (P＜0.01); To the local sign curative effect of prostate, be respectively 92.3% and 71.3% such as the hard effective percentage tough and tenderness of body of gland, obviously be better than matched group, two groups of comparing differences remarkable (P＜0.01); Reducing the prostatic fluid leukocyte count, increase the lecithin aspect, the treatment group effective percentage is respectively 95.6% and 93.7%, and matched group is respectively 58.9% and 56. 10/6, and the two comparing difference is (P＜0.01) significantly; Aspect the prostate ultrasound diagnosis, the treatment group effective percentage obviously is better than matched group, and two groups relatively, significant difference (P＜0.01).
Drug therapy prostatic hyperplasia 200 examples of the present invention, clinical total effective rate reaches 90.0%, the total effective rates such as, urinate smooth, difficulty and pain in micturition clean to the main syndromes that improves prostatic hyperplasia such as nocturia frequency, the sound of rain pattering are all more than 85.0%, obviously be better than matched group, two groups of contrast differences remarkable (P＜0.01); The local sign of prostate such as prostate increase, and matter is hard, tough, the curative effect of disappearence of central groove, and treatment group is respectively 50.6%, 55.8%, 54.5%, matched group is respectively 23.2%, 19.7%, 21.8%, treatment group obviously is better than matched group, and two groups relatively, significant difference (P＜0.01); Prostate ultrasound diagnosis result, aspect the prostate size, the residual urine volume aspect, the treatment group curative effect all is better than matched group, and significant difference (P＜0.01), each parameter value result of urine flow rate compares before and after two groups of treatments, aspect Qmax, AFR, treatment group all is better than matched group, and the two comparing difference is (P＜0.01) significantly.
Its curative effect was comparatively satisfied after Drug therapy chronic prostatitis of the present invention, prostatic hyperplasia serve on two courses for the treatment of course for the treatment of.
During the clinical drug trial of the present invention, get at random 50 routine patients, blood, routine urinalysis, liver, renal function, electrocardiogram are showed no unusually before and after treatment.Illustrate that this medicine is harmless to people body-centered, liver, renal function.Clinically also without obvious adverse reaction.
Motherland's medical science is without the name of disease of chronic prostatitis, prostatic hyperplasia, so unclean according to the swollen pain of its perineum lower abdomen pendant, frequent micturition, urgent micturition, dysurea, nocturia frequency, the sound of rain pattering, thin and delicate and the anus touch of urine line or B ultrasonic detect symptom and the sign that prostate abnormalities changes, surely belong to the disease categories such as " stranguria ", " difficulty in urination ” “ mass in the abdomen ", because of kidney storing essence master water, post two just; Liver channel of foot-Jueyin just follows row and is distributed in prostatic around external genitals; Bladder is hidden body fluid, and department's gasification is so its sick and kidney, liver, bladder are relevant.Its basic pathology factor be damp and hot, expectorant is turbid, blood stasis.Damp and hot life, or because having a liking for the food delicious food, interior life is damp and hot; Or the criminal's of mistake masturbation, impairment of the kidney due to indulgence in sexual activities, vehement in the fire mutually, living wet by heat, the damp and hot knot of fighting.Stop in the damp, make and living expectorant, expectorant accumulates into turbid.The turbid retardance mechanism of qi of wet hot phlegm was stopped up blood and was formed blood stasis, was condensed in the part of the body cavity below the umbilicus, housing the bladder, kidneys and bowels to retention of damp-heat in the interior, the turbid stasis of blood eventually, the retardance mechanism of qi, and stagnation of QI and blood may bring about pain is so perineum, distention and pain in the lower abdomen affects kidney and functioning of bladder, so urgent micturition, frequent micturition, dysurea; Block urinary tract, so it is not smooth to urinate; The turbid stasis of blood is condensed in the liver pulse, so the hardening of prostate quality or hypertrophy; Damp and hot being impairment of the kidney, instability of kidney QI, so the urine line is thin and delicate, nocturia.Combine its pathogenesis, be damp invasion of lower energizer, the turbid stasis of blood stagnates, the stagnation of liver-QI of suffering from a deficiency of the kidney.According to the purport of " interior warp " " disease caused by accumulations of pathogen should be treated with therapy of dispersion " " disease with retention of pathogen in the body should be treated by elimination therapy ", method for making is worked as with eliminating damp-heat, blood circulation promoting and blood stasis dispelling, and it is treating stranguria to detoxify, and kidney tonifying is soothing the liver.Chinese medicine composition Herba Taraxaci of the present invention, Folium Pyrrosiae eliminating damp-heat detoxifcation; Radix Salviae Miltiorrhizae, Semen Persicae, Flos Carthami, Radix Paeoniae Rubra, Myrrha promoting blood circulation to disperse blood clots and relieves pain; Herba Lycopi, the diuresis of Semen Vaccariae promoting blood circulation to remove obstruction in the collateral; Fructus Toosendan, the turbid detumescence of regulating the flow of vital energy of the Radix Angelicae Dahuricae; Fructus Lycii kidney tonifying strengthening the body resistance.The turbid stasis of blood people having the same aspiration and interest of the party, damp and hot and control, giving consideration to both the incidental and fundamental, just and the card feelings.
The specific embodiment
Below in conjunction with specific embodiment the present invention is further described, so that those skilled in the art more understands the present invention, but does not therefore limit the present invention.
The preparation of embodiment 1 capsule
Prescription: Semen Persicae (parched) 85g, Myrrha (parched) 85g, Radix Salviae Miltiorrhizae 85g, Radix Paeoniae Rubra 85g, Flos Carthami 85g, Herba Lycopi 85g, Semen Vaccariae (parched) 85g, Spina Gleditsiae 85g, Herba Patriniae 280g, Herba Taraxaci 280g, Fructus Toosendan 85g, Radix Angelicae Dahuricae 85g, Folium Pyrrosiae 140g, Fructus Lycii 85g.
Preparation method:
(a) Myrrha, Spina Gleditsiae, the Radix Angelicae Dahuricae are ground into fine powder, and be for subsequent use;
(b) all the other Semen Persicaes, Radix Salviae Miltiorrhizae, Radix Paeoniae Rubra, Flos Carthami, Herba Lycopi, Semen Vaccariae (parched), Herba Patriniae, Herba Taraxaci, Fructus Toosendan, Folium Pyrrosiae, Fructus Lycii, extracting in water filters, merging filtrate, filtrate is condensed into thick paste;
(c) add the fine drug powder that makes in the step (a), dry below 80 ℃, be ground into fine powder, mixing is made pharmaceutically active substance.
(d) this active substance is packed into capsule, makes 1000, and get final product.
The preparation of embodiment 2 tablets
Prescription: Semen Persicae (parched) 80g, Myrrha (parched) 90g, Radix Salviae Miltiorrhizae 90g, Radix Paeoniae Rubra 80g, Flos Carthami 90g, Herba Lycopi 80g, Semen Vaccariae (parched) 90g, Spina Gleditsiae 80g, Herba Patriniae 285g, Herba Taraxaci 275, Fructus Toosendan 90g, Radix Angelicae Dahuricae 80g, Folium Pyrrosiae 145g, Fructus Lycii 80g.
Preparation method:
(a) Myrrha, Spina Gleditsiae, the Radix Angelicae Dahuricae are ground into fine powder, and be for subsequent use;
(b) all the other Semen Persicaes, Radix Salviae Miltiorrhizae, Radix Paeoniae Rubra, Flos Carthami, Herba Lycopi, Semen Vaccariae (parched), Herba Patriniae, Herba Taraxaci, Fructus Toosendan, Folium Pyrrosiae, Fructus Lycii, extracting in water filters, merging filtrate, filtrate is condensed into thick paste;
(c) add the fine drug powder that makes in the step (a), dry below 80 ℃, be ground into fine powder, mixing is made pharmaceutically active substance.
(d) this active substance adds the appropriate amount of starch mixing, is pressed into 1000, and get final product.
The preparation of embodiment 3 granules
Prescription: Semen Persicae (parched) 90g, Myrrha (parched) 80g, Radix Salviae Miltiorrhizae 80g, Radix Paeoniae Rubra 90g, Flos Carthami 80g, Herba Lycopi 90g, Semen Vaccariae (parched) 80g, Spina Gleditsiae 90g, Herba Patriniae 275g, Herba Taraxaci 285g, Fructus Toosendan 80g, Radix Angelicae Dahuricae 90g, Folium Pyrrosiae 135g, Fructus Lycii 90g.
Preparation method:
(a) Myrrha, Spina Gleditsiae, the Radix Angelicae Dahuricae are ground into fine powder, and be for subsequent use;
(b) all the other Semen Persicaes, Radix Salviae Miltiorrhizae, Radix Paeoniae Rubra, Flos Carthami, Herba Lycopi, Semen Vaccariae (parched), Herba Patriniae, Herba Taraxaci, Fructus Toosendan, Folium Pyrrosiae, Fructus Lycii, extracting in water filters, merging filtrate, filtrate is condensed into thick paste;
(c) add the fine drug powder that makes in the step (a), dry below 80 ℃, be ground into fine powder, mixing is made pharmaceutically active substance.
(d) this active substance adds an amount of sucrose mixing, makes 1000 bags, and get final product.
The preparation of embodiment 4 pills
Prescription: Semen Persicae (parched) 70g, Myrrha (parched) 100g, Radix Salviae Miltiorrhizae 70g, Radix Paeoniae Rubra 70g, Flos Carthami 100g, Herba Lycopi 70g, Semen Vaccariae (parched) 100g, Spina Gleditsiae 70g, Herba Patriniae 295g, Herba Taraxaci 265g, Fructus Toosendan 70g, Radix Angelicae Dahuricae 100g, Folium Pyrrosiae 155g, Fructus Lycii 100g.
Preparation method:
(a) Myrrha, Spina Gleditsiae, the Radix Angelicae Dahuricae are ground into fine powder, and be for subsequent use;
(b) all the other Semen Persicaes, Radix Salviae Miltiorrhizae, Radix Paeoniae Rubra, Flos Carthami, Herba Lycopi, Semen Vaccariae (parched), Herba Patriniae, Herba Taraxaci, Fructus Toosendan, Folium Pyrrosiae, Fructus Lycii, extracting in water filters, merging filtrate, filtrate is condensed into thick paste;
(c) add the fine drug powder that makes in the step (a), dry below 80 ℃, be ground into fine powder, mixing is made pharmaceutically active substance.
(d) the general ball of this active substance is made 1000 balls, and be get final product.
Embodiment 5: the preparation of capsule
Prescription: Semen Persicae (parched) 100g, Myrrha (parched) 70g, Radix Salviae Miltiorrhizae 100g, Radix Paeoniae Rubra 100g, Flos Carthami 40g, Herba Lycopi 100g, Semen Vaccariae (parched) 70g, Spina Gleditsiae 100g, Herba Patriniae 265g, Herba Taraxaci 295g, Fructus Toosendan 70g, Radix Angelicae Dahuricae 100g, Folium Pyrrosiae 125g, Fructus Lycii 70g.
Preparation method:
(a) Myrrha, Spina Gleditsiae, the Radix Angelicae Dahuricae are ground into fine powder, and be for subsequent use;
(b) all the other Semen Persicaes, Radix Salviae Miltiorrhizae, Radix Paeoniae Rubra, Flos Carthami, Herba Lycopi, Semen Vaccariae (parched), Herba Patriniae, Herba Taraxaci, Fructus Toosendan, Folium Pyrrosiae, Fructus Lycii, extracting in water filters, merging filtrate, filtrate is condensed into thick paste;
(c) add the fine drug powder that makes in the step (a), dry below 80 ℃, be ground into fine powder, mixing is made pharmaceutically active substance.
(d) this active substance is packed into capsule, makes 1000, and get final product.
Claims (7)
1. Chinese medicine composition that is used for the treatment of prostatitis, prostatic hyperplasia is prepared from by the traditional Chinese medicinal composition raw materials of following weight proportion:
Semen Persicae (parched) 70-100 part, Myrrha (parched) 70-100 part, Radix Salviae Miltiorrhizae 70-100 part, Radix Paeoniae Rubra 70-100 part, Flos Carthami 70-100 part, Herba Lycopi 70-100 part, Semen Vaccariae (parched) 70-100 part, Spina Gleditsiae 70-100 part, Herba Patriniae 265-295 part, Herba Taraxaci 265-295 part, Fructus Toosendan 70-100 part, Radix Angelicae Dahuricae 70-100 part, Folium Pyrrosiae 125-155 part, Fructus Lycii 70-100 part.
2. the Chinese medicine composition that is used for the treatment of prostatitis, prostatic hyperplasia according to claim 1, made by the traditional Chinese medicinal composition raw materials of following weight proportion:
Semen Persicae (parched) 80-90 part, Myrrha (parched) 80-90 part, Radix Salviae Miltiorrhizae 80-90 part, Radix Paeoniae Rubra 80-90 part, Flos Carthami 80-90 part, Herba Lycopi 80-90 part, Semen Vaccariae (parched) 80-90 part, Spina Gleditsiae 80-90 part, Herba Patriniae 275-285 part, Herba Taraxaci 275-285 part, Fructus Toosendan 80-90 part, Radix Angelicae Dahuricae 80-90 part, Folium Pyrrosiae 135-145 part, Fructus Lycii 80-90 part.
3. the Chinese medicine composition that is used for the treatment of prostatitis, prostatic hyperplasia according to claim 2, made by the traditional Chinese medicinal composition raw materials of following weight proportion:
85 parts of Semen Persicae (parched)s, 85 parts of Myrrha (parched), 85 parts of Radix Salviae Miltiorrhizaes, 85 parts of Radix Paeoniae Rubra, 85 parts on Flos Carthami, 85 parts of Herba Lycopi, 85 parts of Semen Vaccariae (parched)s, 85 parts of Spina Gleditsiaes, 280 parts of Herba Patriniae, 280 parts of Herba Taraxacis, 85 parts of Fructus Toosendans, 85 parts of the Radixs Angelicae Dahuricae, 140 parts of Folium Pyrrosiae, 85 parts of Fructus Lycii.
4. according to claim 1 and 2 or the 3 described Chinese medicine compositions that are used for the treatment of prostatitis, prostatic hyperplasia, it is characterized in that, be the oral formulations form.
5. the Chinese medicine composition that is used for the treatment of prostatitis, prostatic hyperplasia according to claim 4 is characterized in that, described oral formulations is tablet, pill, capsule, granule.
6. the Chinese medicine composition that is used for the treatment of prostatitis, prostatic hyperplasia according to claim 5 is characterized in that, described oral formulations is capsule.
7. the preparation method that is used for the treatment of the Chinese medicine composition of prostatitis, prostatic hyperplasia according to claim 1, through following steps:
(a) Myrrha, Spina Gleditsiae, the Radix Angelicae Dahuricae are ground into fine powder, and be for subsequent use;
(b) all the other Semen Persicaes, Radix Salviae Miltiorrhizae, Radix Paeoniae Rubra, Flos Carthami, Herba Lycopi, Semen Vaccariae (parched), Herba Patriniae, Herba Taraxaci, Fructus Toosendan, Folium Pyrrosiae, Fructus Lycii, extracting in water filters, merging filtrate, filtrate is condensed into thick paste;
(c) add the fine drug powder that makes in the step (a), dry below 80 ℃, be ground into fine powder, mixing is made pharmaceutically active substance;
(d) this active substance mixes separately or with the medicine acceptable carrier, namely can be made into according to the galenic pharmacy conventional method.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2012105414606A CN102961508A (en) | 2012-12-14 | 2012-12-14 | Traditional Chinese medicine composition used for treating prostatitis and benign prostatic hyperplasia |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2012105414606A CN102961508A (en) | 2012-12-14 | 2012-12-14 | Traditional Chinese medicine composition used for treating prostatitis and benign prostatic hyperplasia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN102961508A true CN102961508A (en) | 2013-03-13 |
Family
ID=47792127
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2012105414606A Pending CN102961508A (en) | 2012-12-14 | 2012-12-14 | Traditional Chinese medicine composition used for treating prostatitis and benign prostatic hyperplasia |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102961508A (en) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103656377A (en) * | 2013-11-27 | 2014-03-26 | 夏毓 | Traditional Chinese medicine medicament for internally and externally treating chronic prostatitis |
| CN104666441A (en) * | 2015-03-21 | 2015-06-03 | 陈梦佳 | Traditional Chinese medicine composition for treating prostatic hyperplasia and preparation method of traditional Chinese medicine composition |
| CN104666678A (en) * | 2015-03-21 | 2015-06-03 | 陈梦佳 | Medicament for treating prostatic hyperplasia and preparation method of medicament |
| CN109045156A (en) * | 2018-10-19 | 2018-12-21 | 山东宏济堂制药集团股份有限公司 | Chinese medicine composition, emplastrum and preparation method |
| CN109700891A (en) * | 2019-03-11 | 2019-05-03 | 山西中医药大学 | A kind of pharmaceutical composition of anti-prostatic hyperplasia |
| CN111939047A (en) * | 2020-08-25 | 2020-11-17 | 安徽省库医斯医药用品制造有限公司 | Prostate fumigation treatment chair |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1742903A (en) * | 2005-09-29 | 2006-03-08 | 济南宏济堂制药有限责任公司 | Medicine for treating prostatitis and hyperlasia of prostate |
| CN1806832A (en) * | 2005-01-19 | 2006-07-26 | 北京凯瑞创新医药科技有限公司 | Pharmaceutical composition, its preparation process and quality control method |
-
2012
- 2012-12-14 CN CN2012105414606A patent/CN102961508A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1806832A (en) * | 2005-01-19 | 2006-07-26 | 北京凯瑞创新医药科技有限公司 | Pharmaceutical composition, its preparation process and quality control method |
| CN1742903A (en) * | 2005-09-29 | 2006-03-08 | 济南宏济堂制药有限责任公司 | Medicine for treating prostatitis and hyperlasia of prostate |
Non-Patent Citations (2)
| Title |
|---|
| 吴裕忠: "中医药治疗慢性前列腺炎概况", 《河南中医》, vol. 26, no. 09, 10 September 2006 (2006-09-10), pages 78 - 80 * |
| 张奎军等: "慢性前列腺炎中医治疗进展", 《辽宁中医杂志》, vol. 32, no. 01, 18 January 2005 (2005-01-18), pages 85 - 86 * |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103656377A (en) * | 2013-11-27 | 2014-03-26 | 夏毓 | Traditional Chinese medicine medicament for internally and externally treating chronic prostatitis |
| CN103656377B (en) * | 2013-11-27 | 2016-08-17 | 夏毓 | A kind of Chinese medicine of internal and external application chronic prostatitis |
| CN104666441A (en) * | 2015-03-21 | 2015-06-03 | 陈梦佳 | Traditional Chinese medicine composition for treating prostatic hyperplasia and preparation method of traditional Chinese medicine composition |
| CN104666678A (en) * | 2015-03-21 | 2015-06-03 | 陈梦佳 | Medicament for treating prostatic hyperplasia and preparation method of medicament |
| CN109045156A (en) * | 2018-10-19 | 2018-12-21 | 山东宏济堂制药集团股份有限公司 | Chinese medicine composition, emplastrum and preparation method |
| CN109700891A (en) * | 2019-03-11 | 2019-05-03 | 山西中医药大学 | A kind of pharmaceutical composition of anti-prostatic hyperplasia |
| CN109700891B (en) * | 2019-03-11 | 2021-07-02 | 山西中医药大学 | Pharmaceutical composition for resisting prostatic hyperplasia |
| CN111939047A (en) * | 2020-08-25 | 2020-11-17 | 安徽省库医斯医药用品制造有限公司 | Prostate fumigation treatment chair |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102205107B (en) | Chinese medicinal preparation for treating duodenal ulcer and preparation method thereof | |
| CN102961508A (en) | Traditional Chinese medicine composition used for treating prostatitis and benign prostatic hyperplasia | |
| CN102266508B (en) | Chinese medicinal composition for treating drying syndrome and preparation method and application thereof | |
| CN101019984A (en) | Constipation treating Chinese medicine prepn | |
| CN104001046A (en) | Oral traditional Chinese medicine preparation for treating urinary calculus and preparation method thereof | |
| CN103830632A (en) | Chinese traditional medicine preparation for radically treating psoriasis and multiple skin diseases and preparation method and application thereof | |
| CN1742903B (en) | Medicine for treating prostatitis and hyperlasia of prostate and preparation method thereof | |
| CN104491661B (en) | A kind of Chinese medicine composition for being used to treat prostatitis or hyperplasia of prostate | |
| CN101584758A (en) | A kind of pharmaceutical composition for the treatment of kidney deficiency | |
| CN103169883B (en) | Traditional Chinese medicine for treating infantile jaundice | |
| CN102526640B (en) | Pantoprazole sodium medicine compound and preparation technology thereof | |
| CN104491459A (en) | Traditional Chinese medicine composition for treating tumors | |
| CN101708286B (en) | Chinese patent medicament for treating sjogren's syndrome and intractable oral ulcer, and preparation method thereof | |
| CN103157062A (en) | Medicine composition curing gynaecological mass diseases such as fibroids and preparation method and application thereof | |
| CN101829188B (en) | Medicament for treating urinary infection and lithiasis | |
| CN104800675A (en) | Medicament for treating active ulcerative colitis | |
| CN104888153A (en) | Traditional Chinese medicine preparation for treating hepatic hemangioma and preparation method therefor | |
| CN104095915A (en) | Traditional Chinese medicine composition for treating diabetic foot | |
| CN103417714B (en) | Traditional Chinese medicine composition used for prostate diseases | |
| CN102847060A (en) | Traditional Chinese medicine composition for treating uterine myoma and preparation method thereof | |
| CN106581468A (en) | Preparation method of traditional Chinese medicine capable of treating gastric ulcer | |
| CN105853940A (en) | Traditional Chinese medicine for treating bile disease | |
| CN105561143A (en) | Pharmaceutical composition for treating chronic gastritis and chronic cholecystitis | |
| CN105194526A (en) | Traditional Chinese medicine for treating hepatic calculi | |
| CN102961678B (en) | Traditional Chinese medicine preparation for treating gallstone and cholecystitis and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C53 | Correction of patent of invention or patent application | ||
| CB02 | Change of applicant information |
Address after: Licheng District 250103 Shandong city of Ji'nan province by ten Road No. 30766 Applicant after: Shandong Hongjitang Pharmaceutical Co., Ltd. Address before: Hualong Road, Licheng District, Shandong city of Ji'nan Province, 250100 No. 360 Shandong hongjitang Pharmaceutical Group Co., Ltd. Applicant before: Shandong Hongjitang Pharmaceutical Co., Ltd. |
|
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20130313 |